Our blood metabolic panel results show that GHF-201 is able to correct hypoglycemia and hyperlipidemia and partially restore muscle (creatine kinase) and liver (alanine transferase) damage, all of which characteristically accrue with time in the Agl−/− GSDIII mouse model (Figure 3). This evidence concerns the gene AGL and hyperlipidemia.